[Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity
Joseph Tung, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and the award was recorded at $0. The RSUs vest in three equal installments, with one-third vesting on each of 08/08/2026, 08/08/2027 and 08/08/2028, and the reported ownership form is direct. Following this reported transaction, the RSUs correspond to 29,240 underlying shares.
The filing discloses an equity award that aligns a director with shareholder interests via long-term vesting, but it does not provide the company鈥檚 total outstanding share count or other compensation terms needed to assess dilution or material financial impact.
Joseph Tung, direttore di Shuttle Pharmaceuticals Holdings (SHPH), ha ricevuto 29,240 unit脿 di azioni vincolate (RSU) l'08/08/2025. Ogni RSU conferisce il diritto condizionato a ricevere una azione ordinaria e l'assegnazione 猫 stata registrata a $0. Le RSU maturano in tre tranche uguali, con un terzo che matura l'08/08/2026, un terzo l'08/08/2027 e un terzo l'08/08/2028, e la forma di propriet脿 riportata 猫 diretta. Dopo questa segnalazione, le RSU corrispondono a 29,240 azioni sottostanti.
La comunicazione evidenzia un premio azionario che allinea il direttore agli azionisti tramite un piano di vesting a lungo termine, ma non indica il numero totale di azioni in circolazione n茅 altri termini retributivi necessari per valutare la diluizione o l'impatto finanziario rilevante.
Joseph Tung, director de Shuttle Pharmaceuticals Holdings (SHPH), recibi贸 29,240 unidades restringidas de acciones (RSU) el 08/08/2025. Cada RSU otorga el derecho contingente a recibir una acci贸n ordinaria y la adjudicaci贸n se registr贸 en $0. Las RSU se consolidan en tres cuotas iguales, con un tercio que vence el 08/08/2026, otro tercio el 08/08/2027 y el restante el 08/08/2028, y la forma de propiedad declarada es directa. Tras esta operaci贸n informada, las RSU equivalen a 29,240 acciones subyacentes.
El informe muestra una adjudicaci贸n de acciones que alinea al director con los intereses de los accionistas mediante un calendario de consolidaci贸n a largo plazo, pero no aporta el n煤mero total de acciones en circulaci贸n de la compa帽铆a ni otros t茅rminos de compensaci贸n necesarios para evaluar la diluci贸n o el impacto financiero material.
Shuttle Pharmaceuticals Holdings(SHPH) 鞚挫偓 Joseph Tung鞐愱矊 2025雲� 08鞗� 08鞚检棎 29,240臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)臧� 攵�鞐悩鞐堨姷雼堧嫟. 臧� RSU電� 氤错喌欤� 1欤茧ゼ 氚涭潉 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 頃措嫻 靾橃棳攵勳潃 $0搿� 瓿勳儊霅橃棃鞀惦媹雼�. RSU電� 霃欖澕頃� 3須� 攵勴暊搿� 氩犾姢韺呺悩氅� 臧侁皝 2026雲� 08鞗� 08鞚�, 2027雲� 08鞗� 08鞚�, 2028雲� 08鞗� 08鞚检棎 1/3鞌� 氩犾姢韸鸽惄雼堧嫟. 氤搓碃霅� 靻岇湢 順曧儨電� 歆侅爲 靻岇湢鞛呺媹雼�. 鞚� 氤搓碃 鞚错泟 RSU電� 29,240欤检潣 旮办磮 欤检嫕鞐� 頃措嫻頃╇媹雼�.
鞁犼碃靹滌棎電� 鞛リ赴 氩犾姢韺呾潉 韱淀暣 鞚挫偓鞚� 鞚错暣甏�瓿勲ゼ 欤检＜鞕� 鞚检箻鞁滍偆電� 欤检嫕 氤挫儊鞚� 瓿店皽霅橃柎 鞛堨溂雮�, 須岇偓鞚� 齑� 氚滍枆 欤检嫕 靾橂倶 頋劃霃� 霕愲姅 鞛鞝� 欷戨寑靹膘潉 韽夑皜頃橂姅 雿� 頃勳殧頃� 旮绊儉 氤挫儊 臁瓣贝鞚� 鞝滉车霅橁碃 鞛堨 鞎婌姷雼堧嫟.
Joseph Tung, administrateur de Shuttle Pharmaceuticals Holdings (SHPH), s'est vu attribuer 29,240 unit茅s d'actions restreintes (RSU) le 08/08/2025. Chaque RSU conf猫re le droit conditionnel de recevoir une action ordinaire et l'attribution a 茅t茅 comptabilis茅e 脿 0 $. Les RSU acqui猫rent leurs droits en trois versements 茅gaux, un tiers respectivement les 08/08/2026, 08/08/2027 et 08/08/2028, et la forme de d茅tention d茅clar茅e est directe. 脌 la suite de cette op茅ration d茅clar茅e, les RSU correspondent 脿 29,240 actions sous-jacentes.
Le d茅p么t r茅v猫le une attribution d'actions qui aligne un administrateur sur les int茅r锚ts des actionnaires via un calendrier d'acquisition 脿 long terme, mais il ne fournit pas le nombre total d'actions en circulation de la soci茅t茅 ni d'autres modalit茅s de r茅mun茅ration n茅cessaires pour 茅valuer la dilution ou l'impact financier significatif.
Joseph Tung, Direktor von Shuttle Pharmaceuticals Holdings (SHPH), erhielt am 08.08.2025 29,240 Restricted Stock Units (RSUs). Jede RSU gew盲hrt das bedingte Recht, eine Stammaktie zu erhalten, und die Zuteilung wurde mit $0 verbucht. Die RSUs vesten in drei gleichen Tranchen, wobei jeweils ein Drittel am 08.08.2026, 08.08.2027 und 08.08.2028 f盲llig wird, und die gemeldete Besitzform ist direkt. Nach dieser Meldung entsprechen die RSUs 29,240 zugrunde liegenden Aktien.
Die Einreichung offenbart eine Aktienzuteilung, die den Direktor 眉ber langfristige Vesting-Bedingungen mit den Interessen der Aktion盲re in Einklang bringt, liefert jedoch nicht die Gesamtzahl der ausstehenden Aktien des Unternehmens oder weitere Verg眉tungsbedingungen, die zur Beurteilung einer Verw盲sserung oder eines wesentlichen finanziellen Effekts erforderlich w盲ren.
- Alignment with shareholders: The director grant vests over multiple years, linking compensation to long-term performance
- Size of award disclosed: 29,240 RSUs explicitly reported and documented
- No outstanding share count provided: The filing does not include company share totals, so potential dilution cannot be assessed from this form
- No additional compensation terms disclosed: Other economic terms or reasons for the grant are not included in this Form 4
Insights
TL;DR: Director equity grant of 29,240 RSUs with multi-year vesting signals alignment but is likely routine and not clearly material.
The grant to Joseph Tung vests one-third annually over three years, which is a standard retention and alignment structure for board members. The award is directly held and converts one-for-one to common shares, recorded at $0, which indicates a typical restricted award rather than a purchase. The filing lacks context on outstanding shares or board compensation policy, so the governance implication is positive for alignment but the materiality to shareholders cannot be quantified from this form alone.
TL;DR: A 29,240-RSU grant is disclosed; without share-count context this is informational and unlikely to be material to valuation.
This Form 4 shows an acquisition (grant) of 29,240 RSUs exercisable into 29,240 common shares and vesting across 2026鈥�2028. The reported price is $0, consistent with standard RSU awards rather than an option exercise or purchase. Because the filing does not disclose the company鈥檚 outstanding shares or other recent insider activity, the transaction should be treated as routine insider compensation rather than a market-moving event based solely on the information provided.
Joseph Tung, direttore di Shuttle Pharmaceuticals Holdings (SHPH), ha ricevuto 29,240 unit脿 di azioni vincolate (RSU) l'08/08/2025. Ogni RSU conferisce il diritto condizionato a ricevere una azione ordinaria e l'assegnazione 猫 stata registrata a $0. Le RSU maturano in tre tranche uguali, con un terzo che matura l'08/08/2026, un terzo l'08/08/2027 e un terzo l'08/08/2028, e la forma di propriet脿 riportata 猫 diretta. Dopo questa segnalazione, le RSU corrispondono a 29,240 azioni sottostanti.
La comunicazione evidenzia un premio azionario che allinea il direttore agli azionisti tramite un piano di vesting a lungo termine, ma non indica il numero totale di azioni in circolazione n茅 altri termini retributivi necessari per valutare la diluizione o l'impatto finanziario rilevante.
Joseph Tung, director de Shuttle Pharmaceuticals Holdings (SHPH), recibi贸 29,240 unidades restringidas de acciones (RSU) el 08/08/2025. Cada RSU otorga el derecho contingente a recibir una acci贸n ordinaria y la adjudicaci贸n se registr贸 en $0. Las RSU se consolidan en tres cuotas iguales, con un tercio que vence el 08/08/2026, otro tercio el 08/08/2027 y el restante el 08/08/2028, y la forma de propiedad declarada es directa. Tras esta operaci贸n informada, las RSU equivalen a 29,240 acciones subyacentes.
El informe muestra una adjudicaci贸n de acciones que alinea al director con los intereses de los accionistas mediante un calendario de consolidaci贸n a largo plazo, pero no aporta el n煤mero total de acciones en circulaci贸n de la compa帽铆a ni otros t茅rminos de compensaci贸n necesarios para evaluar la diluci贸n o el impacto financiero material.
Shuttle Pharmaceuticals Holdings(SHPH) 鞚挫偓 Joseph Tung鞐愱矊 2025雲� 08鞗� 08鞚检棎 29,240臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)臧� 攵�鞐悩鞐堨姷雼堧嫟. 臧� RSU電� 氤错喌欤� 1欤茧ゼ 氚涭潉 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 頃措嫻 靾橃棳攵勳潃 $0搿� 瓿勳儊霅橃棃鞀惦媹雼�. RSU電� 霃欖澕頃� 3須� 攵勴暊搿� 氩犾姢韺呺悩氅� 臧侁皝 2026雲� 08鞗� 08鞚�, 2027雲� 08鞗� 08鞚�, 2028雲� 08鞗� 08鞚检棎 1/3鞌� 氩犾姢韸鸽惄雼堧嫟. 氤搓碃霅� 靻岇湢 順曧儨電� 歆侅爲 靻岇湢鞛呺媹雼�. 鞚� 氤搓碃 鞚错泟 RSU電� 29,240欤检潣 旮办磮 欤检嫕鞐� 頃措嫻頃╇媹雼�.
鞁犼碃靹滌棎電� 鞛リ赴 氩犾姢韺呾潉 韱淀暣 鞚挫偓鞚� 鞚错暣甏�瓿勲ゼ 欤检＜鞕� 鞚检箻鞁滍偆電� 欤检嫕 氤挫儊鞚� 瓿店皽霅橃柎 鞛堨溂雮�, 須岇偓鞚� 齑� 氚滍枆 欤检嫕 靾橂倶 頋劃霃� 霕愲姅 鞛鞝� 欷戨寑靹膘潉 韽夑皜頃橂姅 雿� 頃勳殧頃� 旮绊儉 氤挫儊 臁瓣贝鞚� 鞝滉车霅橁碃 鞛堨 鞎婌姷雼堧嫟.
Joseph Tung, administrateur de Shuttle Pharmaceuticals Holdings (SHPH), s'est vu attribuer 29,240 unit茅s d'actions restreintes (RSU) le 08/08/2025. Chaque RSU conf猫re le droit conditionnel de recevoir une action ordinaire et l'attribution a 茅t茅 comptabilis茅e 脿 0 $. Les RSU acqui猫rent leurs droits en trois versements 茅gaux, un tiers respectivement les 08/08/2026, 08/08/2027 et 08/08/2028, et la forme de d茅tention d茅clar茅e est directe. 脌 la suite de cette op茅ration d茅clar茅e, les RSU correspondent 脿 29,240 actions sous-jacentes.
Le d茅p么t r茅v猫le une attribution d'actions qui aligne un administrateur sur les int茅r锚ts des actionnaires via un calendrier d'acquisition 脿 long terme, mais il ne fournit pas le nombre total d'actions en circulation de la soci茅t茅 ni d'autres modalit茅s de r茅mun茅ration n茅cessaires pour 茅valuer la dilution ou l'impact financier significatif.
Joseph Tung, Direktor von Shuttle Pharmaceuticals Holdings (SHPH), erhielt am 08.08.2025 29,240 Restricted Stock Units (RSUs). Jede RSU gew盲hrt das bedingte Recht, eine Stammaktie zu erhalten, und die Zuteilung wurde mit $0 verbucht. Die RSUs vesten in drei gleichen Tranchen, wobei jeweils ein Drittel am 08.08.2026, 08.08.2027 und 08.08.2028 f盲llig wird, und die gemeldete Besitzform ist direkt. Nach dieser Meldung entsprechen die RSUs 29,240 zugrunde liegenden Aktien.
Die Einreichung offenbart eine Aktienzuteilung, die den Direktor 眉ber langfristige Vesting-Bedingungen mit den Interessen der Aktion盲re in Einklang bringt, liefert jedoch nicht die Gesamtzahl der ausstehenden Aktien des Unternehmens oder weitere Verg眉tungsbedingungen, die zur Beurteilung einer Verw盲sserung oder eines wesentlichen finanziellen Effekts erforderlich w盲ren.
FAQ
What did Joseph Tung report in the SHPH Form 4?
How do the 29,240 RSUs vest for SHPH director Joseph Tung?
Is the reported ownership direct or indirect for the SHPH grant?
Was any cash paid for the RSUs in the SHPH Form 4?
Does the Form 4 state how many shares the RSUs represent after vesting?
